Detalhe da pesquisa
1.
Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
BMC Infect Dis;
21(1): 222, 2021 Feb 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33637050
2.
Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries.
Prev Med;
139: 106182, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32593732
3.
Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
Pharmacoepidemiol Drug Saf;
29(3): 270-278, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31950545
4.
Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
BMC Infect Dis;
19(1): 484, 2019 May 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31146698
5.
Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients.
Cost Eff Resour Alloc;
17: 26, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31827410
6.
Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.
Respir Res;
18(1): 86, 2017 05 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28482883
7.
Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
COPD;
14(1): 80-85, 2017 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27819513
8.
Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
BMC Infect Dis;
21(1): 340, 2021 Apr 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33845777
9.
Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Respir Res;
16: 141, 2015 Nov 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26572740
10.
Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK.
Cost Eff Resour Alloc;
13: 22, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26692823
11.
Resource Use and Costs up to Two Years Post Diagnosis Among Newly Diagnosed COPD Patients in the UK Primary Care Setting: A Retrospective Cohort Study.
COPD;
12(3): 267-75, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25093809
12.
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
Value Health;
14(1): 15-23, 2011 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21211482
13.
Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
J Manag Care Spec Pharm;
27(7): 891-903, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34185564
14.
Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
Value Health;
13(2): 188-95, 2010.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19883407
15.
Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.
J Manag Care Spec Pharm;
26(2): 104-116, 2020 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32011956
16.
"It made me more confident that I have it under control": Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain.
PLoS One;
15(5): e0232473, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32357195
17.
Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
AIDS;
33(11): 1739-1749, 2019 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31180906
18.
COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Int J Chron Obstruct Pulmon Dis;
14: 51-63, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30587961
19.
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Lancet Infect Dis;
19(3): 253-264, 2019 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30732940
20.
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Value Health Reg Issues;
16: 74-80, 2018 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30296624